BCL2 and cancer: Recent studies have further emphasized that restoration of PTEN function combined with radiotherapy (RT), as well as dual inhibition of the PI3K/Akt signaling axis and antiapoptotic BCL‐XL in PTEN‐deficient tumors, can effectively overcome BCL‐2‐mediated survival advantages, highlighting the multifaceted regulation of apoptotic pathways in diverse cancer contexts [36, 37, 38].